查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553615

甲狀腺疾病治療的市場規模、佔有率和趨勢分析報告：按適應症、藥物、分銷管道、給藥途徑、地區和細分市場預測，2024-2030年

Thyroid Gland Disorder Treatment Market Size, Share & Trends Analysis Report By Indication (Hypothyroidism), By Drug (Levothyroxine), By Distribution Channel, By Route of Administration, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

甲狀腺疾病治療市場的成長與趨勢：

預計2030年全球甲狀腺疾病治療市場規模將達28.4億美元，2024年至2030年複合年成長率預計為3.6%。

由於全球甲狀腺疾病的盛行率不斷上升，預計未來幾年抗甲狀腺藥物的需求將會增加。甲狀腺機能低下症是美國住院的主要原因之一，醫療保健專業人員和患者對疾病管理意識的提高也是推動市場成長的因素之一。有各種私人和公共組織致力於傳播疾病管理意識，包括英國甲狀腺基金會、美國甲狀腺協會 (ATA) 和加拿大甲狀腺基金會。

對這些藥物的需求不斷增加，導致了各種治療甲狀腺疾病的學名藥藥物的學名藥的開發。學名藥製造商正在專注於獲得競爭優勢的策略，包括新產品開發、加強分銷管道、地理擴張以及與其他公司的產品合作。此外，核准品牌藥學名藥藥的監管機構努力克服產品核可延遲的問題，並以更低的價格提供這些藥物。預計這將在預測期內提振市場。

甲狀腺疾病治療市場報告亮點

  • 甲狀腺機能低下症在市場上佔據主導地位，到 2023 年將佔 68.7%的市場佔有率，預計在整個預測期內將保持其地位。另一方面，由於格雷夫茲病的盛行率不斷增加，預計甲狀腺功能亢進將穩定成長。
  • 口服給藥是最優選或最常用的給藥途徑，因為其方便且簡單有助於提高病患的依從性。這個市場是由強大的口服抗甲狀腺藥物產品線推動的。
  • 由於門診處方藥支出隨著整體醫療保健支出的增加而增加，批發分銷在 2023 年佔據最大的市場收益佔有率，達到 46.7%。預計電子商務將在未來幾年內出現利潤豐厚的成長。
  • 亞洲國家，尤其是印度和中國，預計未來幾年將顯著成長。
  • 市場分散，製藥公司規模各異。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章甲狀腺疾病治療市場的變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 甲狀腺疾病治療市場分析工具
    • 波特的分析
    • PESTEL分析

第4章 甲狀腺疾病治療市場：按適應症估計與趨勢分析

  • 細分儀表板
  • 甲狀腺疾病治療市場：2023年及2030年適應症變化分析
  • 甲狀腺機能低下症
  • 甲狀腺功能亢進症

第5章甲狀腺疾病治療市場：按藥物估計和趨勢分析

  • 細分儀表板
  • 甲狀腺疾病治療市場：2023年及2030年藥物波動分析
  • 左旋甲狀腺素
  • 碘甲狀腺素
  • 丙硫氧嘧啶
  • 咪唑類化合物
  • 其他

第6章甲狀腺疾病治療市場：依通路估算與趨勢分析

  • 細分儀表板
  • 甲狀腺疾病治療市場：2023年及2030年通路變化分析
  • 批發銷售
  • 零售
  • 網路藥房

第7章甲狀腺疾病治療市場：依途徑估計與趨勢分析

  • 細分儀表板
  • 甲狀腺疾病治療市場：2023 年和 2030 年按給藥途徑的變化分析
  • 口服
  • 靜脈

第8章甲狀腺疾病治療市場：區域估計與趨勢分析

  • 2023 年和 2030 年按地區分類的甲狀腺疾病治療市場佔有率
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Abbvie Inc.
    • Amgen Inc.
    • GSK Plc
    • Merck KGaA
    • Viatris Inc.
    • Novartis AG
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Elexis Inc.
    • IBSA Pharma（IBSA Group）
簡介目錄
Product Code: GVR-2-68038-118-4

Thyroid Gland Disorder Treatment Market Growth & Trends:

The global thyroid gland disorder treatment market size is expected to reach USD 2.84 billion in 2030 and is projected to grow at a CAGR of 3.6% from 2024 to 2030. An increase in the prevalence of thyroid diseases around the globe is expected to drive demand for anti-thyroid drugs in the coming years. Hypothyroidism is one of the leading causes of hospitalization in U.S. Growing awareness about disease management amongst healthcare professionals and patients is another factor augmenting the market growth. There are various private and public organizations working toward spreading awareness related to disease management, such as the British Thyroid Foundation, The American Thyroid Association (ATA), and Thyroid Foundation of Canada.

Rising demand for these drugs has resulted in the development of various generic equivalents of branded drugs to treat thyroid gland disorders. Generic drug manufacturers are focusing on strategies such as new product development, distribution channel enhancement, regional expansions, and collaborations with other companies for marketing their products to gain an edge over the competition. In addition, regulatory authorities that approve generic versions of branded drugs are working to overcome delays in product approvals and enable the availability of these drugs at a lower price. This is expected to boost the market over the forecast period.

Thyroid Gland Disorder Treatment Market Report Highlights:

  • Hypothyroidism dominated the market and accounted for a market share of 68.7% in 2023 and is expected to maintain its position throughout the forecast period. On the other hand, hyperthyroidism is expected to witness steady growth on account of the increase in the incidence of Graves' disease
  • The oral route is the most preferred or most frequently used route of administration owing to its convenience and simplicity, which helps improve patient compliance. The market is driven by the presence of a strong pipeline of oral anti-thyroid medications
  • Wholesale distribution accounted for the largest market revenue share of 46.7% in 2023 owing to increasing spending on outpatient prescription drugs along with overall healthcare expenditure. E-commerce is expected to witness lucrative growth in the coming years
  • Asian countries, especially India and China, are expected to observe remarkable growth in the coming years
  • The market is fragmented in nature, with the presence of various large and small pharmaceutical players

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Thyroid Gland Disorder Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Thyroid Gland Disorder Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Thyroid Gland Disorder Treatment Market: Indication Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Thyroid Gland Disorder Treatment Market: Indication Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Hypothyroidism
    • 4.3.1. Hypothyroidism Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Hyperthyroidism
    • 4.4.1. Hyperthyroidism Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Thyroid Gland Disorder Treatment Market: Drug Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Thyroid Gland Disorder Treatment Market: Drug Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Levothyroxine
    • 5.3.1. Levothyroxine Thyroid Gland Disorder Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Liothyroxine
    • 5.4.1. Liothyroxine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Propylthiouracil
    • 5.5.1. Liothyroxine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Imidazole-based compounds
    • 5.6.1. Imidazole-based compounds Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Thyroid Gland Disorder Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Thyroid Gland Disorder Treatment Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Wholesale Distribution
    • 6.3.1. Wholesale Distribution Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Sales
    • 6.4.1. Retail Sales Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacy
    • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Thyroid Gland Disorder Treatment Market: Route of Administration Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Thyroid Gland Disorder Treatment Market: Route of Administration Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Oral
    • 7.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Intravenous
    • 7.4.1. Intravenous Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Thyroid Gland Disorder Treatment Market: Regional Estimates & Trend Analysis

  • 8.1. Thyroid Gland Disorder Treatment Market Share, By Region, 2023 & 2030 (USD Million)
  • 8.2. North America
    • 8.2.1. North America Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Sweden Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. China Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. Thailand
      • 8.4.6.1. Thailand Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Abbvie Inc.
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Amgen Inc.
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. GSK Plc
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Merck KGaA
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. Viatris Inc.
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Novartis AG
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. Pfizer Inc.
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Takeda Pharmaceutical Company Limited
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Elexis Inc.
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. IBSA Pharma (IBSA Group)
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives